2-(Pyrrolidin-1-yl)but-3-enenitrile | 74603-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 2-(Pyrrolidin-1-yl)but-3-enenitrile
• 英文别名: 2-pyrrolidin-1-ylbut-3-enenitrile
• CAS: 74603-43-3
• 化学式: C₈H₁₂N₂
• 分子量: 136.19
• InChiKey: ATIFZEHRVNGHMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
  申请人：——

  公开号：US20040039044A1

  公开（公告）日：2004-02-26

  Novel aminoalkylpyrrolidine 5-HT 7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.

  揭示了新型氨基烷基吡咯啉5-HT7受体配体，制备这种配体的方法，用于制备受体配体的中间化合物，包括受体配体的药物组合物，以及利用受体配体治疗睡眠障碍、疼痛、抑郁症和精神分裂症的方法。受体配体具有如下式（1）：其中式中的变量如本文所定义，并且包括其药用可接受的盐、溶剂化合物、活性代谢物或前药。
• AMINOALKYLPYRROLIDINE SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SYNTHESIS
  申请人：Warner-Lambert Company LLC

  公开号：EP1339677A1

  公开（公告）日：2003-09-03
• US4501695A
  申请人：——

  公开号：US4501695A

  公开（公告）日：1985-02-26
• [EN] AMINOALKYLPYRROLIDINE SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SYNTHESIS<br/>[FR] LIGANDS DES RECEPTEURS DE SEROTONINE AMINOALKYLPYRROLIDINE ET COMPOSITIONS, LEURS UTILISATIONS PHARMACEUTIQUES, ET PROCEDES POUR LEUR SYNTHESE
  申请人：WARNER LAMBERT CO

  公开号：WO2002036560A1

  公开（公告）日：2002-05-10

  Novel aminoalkylpyrrolidine 5-HT7 receptor ligands, methods of preparing such ligands, intermediate compounds useful in the preparation of the receptor ligands, pharmaceutical compositions comprising the receptor ligands, and methods of treating sleep disorders, pain, depression, and schizophrenia employing the receptor ligands are disclosed. The receptor ligands have formula (1): wherein the formula variables are as defined herein, and pharmaceutically acceptable salts, solvates, active metabolites, or prodrugs thereof.